✦ LIBER ✦

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial

✍ Scribed by Hueber, Wolfgang (author);Sands, Bruce E. (author);Lewitzky, Steve (author);Vandemeulebroecke, Marc (author);Reinisch, Walter (author);Higgins, Peter D.R. (author);Wehkamp, Jan (author);Feagan, Brian G. (author);Yao, Michael D. (author);Karczewski, Marek (author);Karczewski, Jacek (author);Pezous, Nicole (author);Bek, Stephan (author);Bruin, Gerard (author);Mellgard, Bjoern (author);Berger, Claudia (author);Londei, Marco (author);Bertolino, Arthur P. (author);Tougas, Gervais (author);Travis, Simon P.L. (author)

Book ID: 115538150
Publisher: BMJ Publishing Group
Year: 2012
Tongue: English
Weight: 304 KB
Volume: 61
Category: Article
ISSN: 0017-5749
DOI: 10.1136/gutjnl-2011-301668

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial

✍ Hueber, Wolfgang (author);Sands, Bruce E. (author);Lewitzky, Steve (author);Vand 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB

Secukinumab, a human anti-IL-17A monoclo

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

✍ Hueber, W.; Sands, B. E.; Lewitzky, S.; Vandemeulebroecke, M.; Reinisch, W.; Hig 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 304 KB

Efficacy and safety of secukinumab, a fu

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. 📂 Article 📅 2013 🏛 BMJ Publishing Group 🌐 English ⚖ 471 KB

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A randomized, placebo-controlled trial o

A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with moderate to severe Crohn's disease

✍ William J. Sandborn; Brian Feagan; Graham Radford-Smith; Agota Kovacs; Robert En 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB